Holen Sie sich die Stockscreener-App
1.39
0.71%
-0.01
Handel nachbörslich:
1.37
-0.02
-1.44%
Schlusskurs vom Vortag:
$1.40
Offen:
$1.4
24-Stunden-Volumen:
258.69K
Relative Volume:
0.34
Marktkapitalisierung:
$43.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.00M
KGV:
-0.50
EPS:
-2.78
Netto-Cashflow:
$-55.26M
1W Leistung:
+8.59%
1M Leistung:
+17.80%
6M Leistung:
-75.18%
1J Leistung:
-81.59%
1-Tages-Spanne:
$1.34
$1.4295
1-Wochen-Bereich:
$1.255
$1.4295
52-Wochen-Spanne:
$1.05
$10.16
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Firmenname
Acrivon Therapeutics Inc
Sektor
Branche
Telefon
617-207-8979
Adresse
480 ARSENAL WAY, SUITE 100, WATERTOWN
Vergleichen Sie ACRV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.39 | 40.13M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-05 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-31 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-12-15 | Fortgesetzt | Jefferies | Buy |
| 2023-10-05 | Eingeleitet | Maxim Group | Buy |
| 2023-06-02 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-04-27 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2023-04-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-12-12 | Eingeleitet | Jefferies | Buy |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Acrivon Therapeutics Inc Aktie (ACRV) Neueste Nachrichten
Acrivon Therapeutics Inc. Stock Analysis and ForecastAccelerated earnings growth - jammulinksnews.com
Is Acrivon Therapeutics Inc. a good long term investmentHigh-octane investment gains - jammulinksnews.com
What analysts say about Acrivon Therapeutics Inc. stockHigh-velocity gains - Autocar Professional
How high can Acrivon Therapeutics Inc. stock price go in 2025Smart Money Signals - Newser
Here's Why We're Watching Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation - Yahoo Finance
What drives Acrivon Therapeutics Inc. stock priceConsistently superior profits - printweek.in
Is Acrivon Therapeutics Inc. stock a good hedge against inflationSolid Return Trade Selections - beatles.ru
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of “Buy” from Analysts - Defense World
Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Target Price at $17.71 - Defense World
What makes Acrivon Therapeutics Inc. stock price move sharplyFree Stock Market Real-Time Monitoring - Newser
Cantor Fitzgerald sets Acrivon stock to Overweight on AP3 platform - MSN
How Acrivon Therapeutics Inc. stock performs during market volatilityAlpha Stock Ideas - Newser
Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsight - GlobeNewswire Inc.
Why Acrivon Therapeutics Inc. stock attracts strong analyst attentionExpert Backed Predictions - Newser
(ACRV) Investment Analysis and Advice - news.stocktradersdaily.com
Acrivon Therapeutics (NASDAQ:ACRV) Trading 0.7% Higher – Still a Buy? - Defense World
Acrivon Therapeutics, Inc.(NasdaqGM: ACRV) dropped from S&P Global BMI Index - MarketScreener
Learn to Evaluate (ACRV) using the Charts - news.stocktradersdaily.com
Acrivon Therapeutics Holds Annual Stockholders Meeting - TipRanks
Analysts Offer Predictions for ACRV FY2026 Earnings - Defense World
Long Term Trading Analysis for (ACRV) - news.stocktradersdaily.com
Nuveen Asset Management LLC Sells 12,377 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Northern Trust Corp Has $706,000 Stock Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of “Buy” from Analysts - Defense World
Acrivon Therapeutics: Promising Clinical Developments and Strategic Focus Support Buy Rating - TipRanks
FY2025 EPS Estimate for Acrivon Therapeutics Cut by Analyst - Defense World
Q3 EPS Forecast for Acrivon Therapeutics Boosted by Analyst - Defense World
Finanzdaten der Acrivon Therapeutics Inc-Aktie (ACRV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):